Physician profile
Lacey S Uphaus
NPI 1851119267
$1,203.98
in general payments reported to CMS, 2019-2025
17 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $59.57 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $182.58 | 2024-2025 | Aristada, Lybalvi |
| Viiv Healthcare Company | $174.66 | 2025 | Apretude |
| Neurocrine Biosciences, INC. | $141.00 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.60 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $95.07 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Collegium Pharmaceutical, INC. | $88.36 | 2025 | Xtampza, Belbuca |
| Vanda Pharmaceuticals INC. | $68.07 | 2025 | Fanapt |
| Abbvie INC. | $67.26 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $61.68 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $57.99 | 2025 | Invega Sustenna, Invega Trinza |
| Pfizer INC. | $32.79 | 2025 | |
| Protega Pharmaceutials INC | $32.21 | 2025 | Roxybond |
| Globus Medical, INC. | $27.18 | 2025 | Senza |
| Dexcom, INC. | $20.84 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $17.40 | 2025 | Trintellix |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $15.32 | 2025 | Brixadi |
| Exact Sciences Corporation | $14.97 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Uphaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.